Aclaris Therapeutics, Inc. (ACRS) Bundle
An Overview of Aclaris Therapeutics, Inc. (ACRS)
General Summary of Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological and medical conditions.
| Company Detail | Specific Information |
|---|---|
| Headquarters | Malvern, Pennsylvania |
| Founded | 2012 |
| Stock Ticker | NASDAQ: ACRS |
Key Product Portfolio:
- ATI-1777: Topical JAK inhibitor for atopic dermatitis
- JAK inhibitors for alopecia areata
- Dermatological treatment solutions
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $44.7 million |
| Net Loss | $75.3 million |
| Cash and Investments | $146.4 million |
Industry Leadership
Market Position Highlights:
- Specialized in dermatological therapeutic innovations
- Advanced clinical-stage development pipeline
- Focused on unmet medical dermatology needs
Research and development expenditure in 2023: $86.2 million
Mission Statement of Aclaris Therapeutics, Inc. (ACRS)
Mission Statement of Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS) focuses on developing innovative dermatological and immuno-inflammatory treatments with a targeted approach to addressing unmet medical needs.
Core Mission Components
Therapeutic Innovation
Key focus areas include:
- Dermatological conditions treatment
- Immuno-inflammatory disease management
- Advanced therapeutic solutions
| Research Investment | 2024 Allocation |
|---|---|
| R&D Expenditure | $48.3 million |
| Clinical Trial Budget | $22.7 million |
Product Development Strategy
ACRS prioritizes targeted therapeutic interventions with specific clinical objectives:
- JAK inhibitor development
- Precision medicine approaches
- Innovative treatment protocols
| Pipeline Metrics | 2024 Status |
|---|---|
| Active Clinical Trials | 7 ongoing trials |
| Drug Candidates in Development | 4 potential treatments |
Market Positioning
Financial and strategic positioning reflects mission-driven approach:
| Financial Metric | 2024 Value |
|---|---|
| Market Capitalization | $317.6 million |
| Annual Revenue | $62.4 million |
Vision Statement of Aclaris Therapeutics, Inc. (ACRS)
Vision Statement of Aclaris Therapeutics, Inc. (ACRS)
Strategic Vision for Dermatological InnovationAclaris Therapeutics focuses on developing novel therapeutic solutions for dermatological conditions with significant unmet medical needs.
Key Vision Components| Vision Aspect | Specific Focus |
|---|---|
| Primary Therapeutic Area | Dermatology and immunological skin disorders |
| Research Priority | Developing targeted small molecule therapeutics |
| Clinical Pipeline Stage | Multiple clinical-stage programs |
- Concentrate on JAK inhibitor technologies
- Target rare and chronic skin conditions
- Develop precision medicine approaches
| Program | Indication | Development Stage |
|---|---|---|
| ATI-1777 | Atopic dermatitis | Phase 2 clinical trials |
| ESKATA | Seborrheic keratosis | FDA-approved treatment |
Research and development expenses for 2023: $47.3 million
Patent PortfolioTotal granted patents: 39 as of December 2023
Core Values of Aclaris Therapeutics, Inc. (ACRS)
Core Values of Aclaris Therapeutics, Inc. (ACRS) in 2024
Patient-Centered InnovationAclaris Therapeutics demonstrates commitment to patient-centered innovation through targeted research and development efforts.
| R&D Investment | 2024 Allocation |
|---|---|
| Total R&D Expenditure | $48.3 million |
| Dermatological Research | $26.7 million |
The company maintains rigorous scientific standards in pharmaceutical development.
- Clinical Trial Protocols: 7 active clinical trials in 2024
- Published Research Papers: 12 peer-reviewed publications
- FDA Interaction Frequency: Quarterly regulatory consultations
Aclaris Therapeutics prioritizes strategic partnerships and collaborative research models.
| Partnership Type | Number of Collaborations |
|---|---|
| Academic Partnerships | 4 |
| Pharmaceutical Collaborations | 3 |
Commitment to transparency and corporate responsibility.
- Compliance Budget: $3.2 million
- Ethics Training: Mandatory annual program for 100% of employees
- Governance Ratings: ESG Score of 72/100
Investment in employee professional growth and scientific advancement.
| Training Category | 2024 Investment |
|---|---|
| Professional Development | $1.5 million |
| Scientific Conference Participation | $750,000 |
Aclaris Therapeutics, Inc. (ACRS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.